ArticleBMC cancer2022

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.

Maria A Pantaleo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.